...Good afternoon. Welcome to Ionis Pharmaceuticals Annual Meeting of Stockholders for 2022. My name is Brett Monia. I'm the Chief Executive Officer of Ionis and I'm really thrilled to provide you with you an update on the great progress we're making at Ionis today. These are my forward-looking statements that I recommend to you to review at your convenience. Today, Ionis is a leading fully integrated biotechnology company, well positioned for substantial growth in the near-term and in the long-term. And the evidence for this is compelling and clear. Today, we have a commercial portfolio of 3 medicines in our commercial, helping our commercial portfolio, led, of course, by our blockbuster medicine SPINRAZA for spinal muscular atrophy. And that portfolio is expected to grow and grow fast and substantially based on our leading -- industry-leading rich, mid- and late-stage pipeline, a pipeline chock-full of many potential transformational medicines that are rapidly advancing the market. In addition,...